Background: Canada's Common Drug Review was implemented to provide publicly funded
drug plans (provincial and federal) with a transparent, rigorous and consistent approach for …

Where you live in Canada and your economic status make a big difference to the sort of
prescription medicine you are likely to receive from public health insurance—although that is …

Background: The CADTH Common Drug Review was established in 2002 to prepare
national health technology assessment reports to guide listing decisions for 18 participating …

Objectives This study was conducted to determine whether establishment of the pan-
Canadian Pharmaceutical Alliance (pCPA) was associated with significant changes in drug …

Prescription drugs are one of the fastest growing cost components of modern health care
systems. Efforts to control escalating costs while simultaneously maximizing population …

Context National public insurance for drugs is often based on evidence of comparative
effectiveness and cost-effectiveness. This study describes how that evidence has been used …

Amir Attaran, Canada Research Chair in Population and Public Health, at the University of
Ottawa, Ontario, is particularly skeptical of the review. A paper he coauthored found that …

• Although pharmaceuticals have the ability to improve health outcomes, they are the fastest
growing component of Canadian health care expenditures.• By analyzing the cost …

Background The upcoming reauthorization of the Prescription Drug User Fee Act focuses on
improving the review process for new drug applications at the Food and Drug Administration …

Background: Information about the timing involved in various stages of making new drugs
available to Canadians is important for understanding how a national pharmacare plan will …